share_log

Longeveron to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Longeveron to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Longeveron將於2024年11月12日報告2024年第三季度財務業績,並舉辦電話會議。
GlobeNewswire ·  11/04 16:05

MIAMI, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report third quarter 2024 financial results and provide a business update on Tuesday, November 12, 2024 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET.

邁阿密,2024年11月4日(GLOBE NEWSWIRE)——開發針對危及生命和慢性衰老相關疾病的細胞療法的臨床階段再生醫學生物技術公司Longeveron Inc.(納斯達克股票代碼:LGVN)今天宣佈,將在美國金融市場收盤後於2024年11月12日星期二公佈2024年第三季度財務業績並提供最新業務情況。該公司將在美國東部時間當天下午 4:30 舉行電話會議和網絡直播。

Conference Call Details:

電話會議詳情:

Conference Call Number: 1.877.407.0789
Conference ID: 13749428
Call me Feature: Click Here
Webcast: Click Here
電話會議號碼: 1.877.407.0789
會議編號: 13749428
給我打電話功能: 點擊這裏
網絡直播: 點擊這裏

An archived replay of the webcast will be available on the "Events & Presentations" section of the Company's website following the conference.

會議結束後,將在公司網站的 「活動與演講」 欄目上提供網絡直播的存檔重播。

About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company's lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer's Disease (AD), and Aging-related Frailty. Lomecel-B development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit or follow Longeveron on LinkedIn, X, and Instagram.

關於 Longeveron Inc.
Longeveron是一家臨床階段的生物技術公司,開發再生藥物以滿足未滿足的醫療需求。該公司的主要研究產品是Lomecel-B,這是一種從年輕、健康的成年捐贈者的骨髓中分離出來的異基因藥物信號傳導細胞(MSC)治療產品。Lomecel-B 具有多種潛在的作用機制,包括促血管、促再生、抗炎以及組織修復和癒合作用,在各種疾病領域具有廣泛的潛在應用。Longeveron目前正在研究三種臨床適應症:左心發育不全綜合症(HLHS)、阿爾茨海默氏病(AD)和衰老相關虛弱。Lomecel-B開發項目已獲得五項不同且重要的FDA認證:HLHS計劃——孤兒藥稱號、快速通道認證和罕見兒科疾病稱號;AD項目——再生醫學高級療法(RMAT)認證和快速通道稱號。欲了解更多信息,請在領英、X和Instagram上訪問或關注Longeveron。

Investor Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com

投資者聯繫人:
德里克·科爾
投資者關係諮詢解決方案
derek.cole@iradvisory.com


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論